These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16796485)

  • 1. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone.
    Shulman LP
    J Womens Health (Larchmt); 2006 Jun; 15(5):584-90. PubMed ID: 16796485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
    Oelkers W
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):255-61. PubMed ID: 15134826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Progestogens in Menopausal Hormone Therapy.
    Liu JH
    Clin Obstet Gynecol; 2021 Dec; 64(4):772-783. PubMed ID: 34593694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?
    Simon JA
    Menopause; 2014 Jul; 21(7):769-83. PubMed ID: 24398406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats.
    Arias-Loza PA; Hu K; Schäfer A; Bauersachs J; Quaschning T; Galle J; Jazbutyte V; Neyses L; Ertl G; Fritzemeier KH; Hegele-Hartung C; Pelzer T
    Hypertension; 2006 Nov; 48(5):994-1001. PubMed ID: 17000933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
    Hargrove JT; Maxson WS; Wentz AC; Burnett LS
    Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
    Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
    Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
    Muhn P; Krattenmacher R; Beier S; Elger W; Schillinger E
    Contraception; 1995 Feb; 51(2):99-110. PubMed ID: 7750297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New progestogens: a review of their effects in perimenopausal and postmenopausal women.
    Sitruk-Ware R
    Drugs Aging; 2004; 21(13):865-83. PubMed ID: 15493951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronized progesterone and its impact on the endometrium and breast vs. progestogens.
    Gompel A
    Climacteric; 2012 Apr; 15 Suppl 1():18-25. PubMed ID: 22432812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.